FDAnews
www.fdanews.com/articles/75421-lantibio-and-apotex-fermentation-announce-a-development-supply-and-royalty-agreement

LANTIBIO AND APOTEX FERMENTATION ANNOUNCE A DEVELOPMENT, SUPPLY AND ROYALTY AGREEMENT

August 16, 2005

Lantibio, Inc. and Apotex Fermentation Inc. (AFI), announced today the signing of an agreement for the development and supply of the lead compound of Lantibio, Moli1901. The molecule is currently in development under two Investigational New Drug Applications (IND) for the treatment of dry eye syndrome and cystic fibrosis. The company expects to commence a Phase II clinical study with Moli1901 in the third quarter of 2005 in dry eye syndrome.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/08-15-2005/0004088781&EDATE=)